Immix Biopharma, Inc.IMMXNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+50.4%
5Y CAGR+131.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+50.4%/yr
Annual compound
5Y CAGR
+131.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
66.6x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$13.70M+20.3%
2024$11.38M+53.7%
2023$7.41M+84.1%
2022$4.02M+228.3%
2021$1.23M+495.8%
2020$205703.00-20.7%
2019$259337.00-